Truvada

Phase 2Small molecule

Gilead

Truvada is one of 103 small molecule programs targeting Hepatitis C. It is currently in Phase 2.

Indications

Total Trials

Active Trials

102

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatitis CActive, not recruiting

Multiple SclerosisEnrolling by invitation

PrepRecruiting

TenofovirCompleted

ProphylaxisWithdrawn

Hepatitis CPreclinical

Active, not recruiting

Multiple SclerosisPhase 2

Enrolling by invitation

PrepPhase 2

Recruiting

TenofovirPreclinical

Completed

ProphylaxisPreclinical

Withdrawn

Competition

Competitive Landscape

145 competitors in Multiple Sclerosis

#DrugCompanyPhaseTrials

Questran

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

2 2

Frexalimab

Sanofi

Phase 3

2 3

Clemastine Fumarate

Novartis

Phase 3

2 4

Activated Charcoal

Sanofi

Phase 3

1 5

Recombinant Zoster Vaccine

MMAXVAX Biotechnology Limited Liability Company

Phase 3

1 6

MRI Contrast-Enhancing Agents

Sanofi

Phase 3

3 7

Tolebrutinib

Sanofi

Phase 3

4 8

Truvada

Gilead

Phase 2

1 9

PBR06

UUniversity Hospital, Bordeaux

Phase 3

3 10

Flomax

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Prevention5 trials

SCOPE: Strategies to Combine PrEP With Prevention Efforts

Withdrawn·FFHI 360·N/A·NCT01832571

The Prevention Options for Women Evaluation Research (POWER) Cohort

Completed·UUniversity of Washington··NCT03490058·2,255 enrolled

3Ps for Prevention Study (Perception, Partners, Pills)

Unknown status·DDesmond Tutu HIV Centre·Phase 4·NCT03142256·200 enrolled

Show 2 more trials

Uptake and Adherence to Daily Oral PrEP as a Primary Prevention Strategy for Young African Women: A Vanguard Study

Completed·HHIV Prevention Trials Network·Phase 4·NCT02732730·451 enrolled

Introducing PrEP Into HIV Combination Prevention - Kenya

Unknown status·LLVCT Health·N/A·NCT02755350·2,100 enrolled

HIV infection4 trials

On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men

Completed·AANRS, Emerging Infectious Diseases·Phase 3·NCT01473472·400 enrolled

Evaluating Once Daily Etravirine in Treatment-Naive Adults With HIV Infection

Completed·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT00959894·80 enrolled

Safety Study of Isentress® + Truvada® in Post-exposure Treatment of HIV Infection

Completed·GGroupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux·Phase 3·NCT01114425·149 enrolled

Show 1 more trial

Evaluation of the Cellular Pharmacology of Tenofovir and Emtricitabine According to HIV Infection Status

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT01040091·34 enrolled

Pre-Exposure Prophylaxis (PrEP)3 trials

Pre-Exposure Prophylaxis (PrEP) Adherence Monitoring Using Dried Blood Spots

Completed·UUniversity of Colorado, Denver·Phase 1/2·NCT02022657·52 enrolled

PrEPared-RN, CAN Nurse-Led Management of High-risk Patients for Pre-Exposure Prophylaxis (PrEP)

Unknown status·CCAN Community Health··NCT06030557·210 enrolled

Demonstrating Safety and Effective Delivery of Daily Oral Pre-exposure Prophylaxis (PrEP) for Sex Workers in India

Completed·UUniversity of Manitoba·Phase 1·NCT02148094·1,325 enrolled

Tenofovir3 trials

Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 Patients

Completed· Gilead logo

Gilead·Phase 4·NCT00106379·52 enrolled

Tenofovir Adherence to Rapidly Guide and Evaluate PrEP and HIV Therapy

Completed·UUniversity of Washington·N/A·NCT03012607·30 enrolled

Exploratory Pharmacodynamic Study of Tenofovir-Based Products

Completed·CCONRAD·Phase 1·NCT02722343·25 enrolled

TED3 trials

Boosted Atazanavir and Truvada Given Once-Daily - BATON Study

Completed· Gilead logo

Gilead·Phase 4·NCT00224445·100 enrolled

Dual Therapy With Boosted Darunavir + Dolutegravir

Completed·TTechnical University of Munich·Phase 3·NCT02486133·269 enrolled

Comparative Study of PK and BE of VM-1500FDC (Fixed-dose Combination) and Elpida® With Truvada® сo-administrated 1 Daily Fasting in Healthy Subjects

Completed·VViriom·Phase 1·NCT03706924·140 enrolled

30 more indications

PrEP2 trials

PrEP, Lube, and the Rectal Mucosa in MSM at Risk of HIV

Completed·EEmory University·Phase 4·NCT02401230·86 enrolled

PrEPsmart 2-1-1 Pilot

Recruiting·PPublic Health Foundation Enterprises, Inc.·Phase 2·NCT06631365·60 enrolled

HIV Prevention2 trials

Reversing the Epidemic in Africa With Choices in HIV Prevention (REACH)

Withdrawn·IInternational Partnership for Microbicides, Inc.·Phase 2·NCT03074786

Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women

Completed·UUniversity of KwaZulu·Phase 2/3·NCT03227731·540 enrolled

Substance Use2 trials

Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users (PrEPSteps)

Completed·—·Phase 3·NCT03512418·30 enrolled

Feasibility and Acceptability of Digital Pills to Monitor PrEP Adherence in MSM With Substance Use

Completed·—·Phase 4·NCT03842436·16 enrolled

Prophylaxis2 trials

Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)

Completed·TThe University of Texas Health Science Center, Houston·Phase 4·NCT01214759·103 enrolled

Pre-Exposure Prophylaxis and Timed Intercourse for HIV-Discordant Couples

Withdrawn·UUniversity of Missouri-Columbia·N/A·NCT02572505

Immunodeficiency2 trials

A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT01632345·342 enrolled

Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02131233·802 enrolled

Treatment2 trials

Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals

Terminated·GGeorge Washington University·Phase 4·NCT00632970·6 enrolled

SONETT: Switch Study to Once Daily HIV Treatment Regimen With Truvada

Completed· Gilead logo

Gilead·Phase 4·NCT00323687·50 enrolled

CLE1 trial

TOTEM: Switch From Other Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to Once Daily Truvada

Completed· Gilead logo

Gilead·Phase 4·NCT00323492·92 enrolled

High Risk1 trial

The Role of Home Packs of HIV PEPSE in High Risk Individuals

Completed·GGuy's and St Thomas' NHS Foundation Trust·Phase 4·NCT04965662·139 enrolled

Women1 trial

FEM-PrEP (Truvada®): Study to Assess the Role of Truvada® in Preventing HIV Acquisition in Women

Completed·FFHI 360·Phase 3·NCT00625404·2,120 enrolled

Interaction1 trial

Pharmacokinetic Interaction Between TRUVADA™ and BILR 355 BS Plus Ritonavir in Healthy Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02253901·33 enrolled

Tuberculosis1 trial

REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment

Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 4·NCT01380080·851 enrolled

Safety and Efficacy1 trial

A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071)

Terminated· Merck & Co. logo

Merck & Co.·Phase 3·NCT00745823·775 enrolled

HIV-11 trial

A Study Exploring an Induction-Maintenance Kaletra-Based Therapy Versus a Sustiva-Based Regimen in Previously Non-Treated, HIV-1/HCV Co-Infected Subjects

Withdrawn·AAbbott·Phase 2·NCT00121017·200 enrolled

Completed·UUniversity of Cincinnati·Phase 4·NCT00885664·60 enrolled

Acceptability1 trial

Acceptability, Safety, and Use of Daily Truvada Pre-Exposure Prophylaxis in Adolescents

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT02213328·148 enrolled

Gastrointestinal1 trial

Effects of the Anti-HIV Pill Truvada on Gene Transcription in the Gastrointestinal Tract of HIV-uninfected Individuals

Completed·UUniversity of Washington··NCT02621242·9 enrolled

Mitochondria1 trial

Switch From Combivir or Trizivir to Truvada - Mitochondrial Effects

Completed·SSt. Luke's-Roosevelt Hospital Center·Phase 4·NCT00960622·17 enrolled

Oral1 trial

Biobehavioral Interventions for HIV-negative, Stimulant Using Men Who Have Sex With Men

Completed·FFriends Research Institute, Inc.·Phase 2·NCT01140880·170 enrolled

Female1 trial

Demonstration Project of PrEP Among Female Sex Workers in Dakar, Senegal

Completed·RRéseau Africain de Recherche sur le SIDA·N/A·NCT02474303·267 enrolled

First-line1 trial

ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy

Completed·PProfessor Francois Venter·Phase 3·NCT03122262·1,110 enrolled

Hepatitis C1 trial

Providing PrEP, Hepatitis C Treatment, and MOUD Through Telemedicine at Greensboro SSP

Completed·—·N/A·NCT05108935·17 enrolled

Methamphetamine1 trial

Contingency Management for Methamphetamine Abstinence and HIV Post-Exposure Prophylaxis in Men Who Have Sex With Men

Completed·FFriends Research Institute, Inc.·Phase 2·NCT00856323·53 enrolled

HIV Pre-Exposure Prophylaxis1 trial

Body Compartment PK for New HIV Pre-exposure Prophylaxis Modalities

Completed·EEmory University·Phase 1·NCT02985996·48 enrolled

Itching1 trial

Peripheral Body Fat Distribution After Switching Zidovudine and Lamivudine to Truvada

Completed· Gilead logo

Gilead·Phase 4·NCT00324649·80 enrolled

Multiple Sclerosis1 trial

Effects of Antiviral Therapies on Epstein-Barr Virus Replication

Enrolling by invitation·MMassachusetts General Hospital·Phase 2·NCT05957913·50 enrolled

Unspecified3 trials

The Maraviroc Darunavir/Ritonavir Once Daily Pharmacokinetic Study

Completed·IImperial College London·Phase 1·NCT01348763·13 enrolled

Dolutegravir in Reservoirs

Terminated·EEmory University·Phase 4·NCT02924389·22 enrolled

Combination of Efavirenz and Truvada - COMET Study

Completed· Gilead logo

Gilead·Phase 4·NCT00224458·400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 56 trial records for Truvada. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Truvada compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Truvada. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gilead company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Gilead

Truvada

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Prevention5 trials

HIV infection4 trials

Pre-Exposure Prophylaxis (PrEP)3 trials

Tenofovir3 trials

TED3 trials

PrEP2 trials

HIV Prevention2 trials

Substance Use2 trials

Prophylaxis2 trials

Immunodeficiency2 trials

Treatment2 trials

CLE1 trial

High Risk1 trial

Women1 trial

Interaction1 trial

Tuberculosis1 trial

Safety and Efficacy1 trial

HIV-11 trial

Dyslipidemia1 trial

Pregnancy1 trial

Tolerance1 trial

Breastfeeding1 trial

Adverse Effect1 trial

Acceptability1 trial

Gastrointestinal1 trial

Mitochondria1 trial

Oral1 trial

Female1 trial

First-line1 trial

Hepatitis C1 trial

Methamphetamine1 trial

HIV Pre-Exposure Prophylaxis1 trial

Itching1 trial

Multiple Sclerosis1 trial

Unspecified3 trials

References

Drug Info

Quick Facts

Related News